2 assets in Malignant Syringoma

Therapeutic assets addressing Malignant Syringoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Malignant Syringoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Malignant Syringoma	National Cancer Institute (NCI)	P2	CCC (53)